BALAXI PHARMACEUTICALS valuation

·UnclassifiedChart ›
Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Price multiples — at each FY-end close
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
44.88×————
0.44×————
0.39×————
Enterprise multiples
0.54×————
16.59×————
23.07×————
Yield
2.2%————
−17.8%————
Reference — adjusted share basis
₹19.71————
₹0.44₹0.26₹4.54−₹0.43₹8.33
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

BALAXI₹19.71

BALAXI PHARMACEUTICALS LIMITED

· Unclassified
₹ CrorePeersPARSTEELCITYLATTEYSCROWNHECPROJECTHINDCONAIROLAMGROBTEAMcap ₹109 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E————44.88
P/B————0.44
P/Sales————0.39
Enterprise Multiples
EV/Sales————0.54
EV/EBITDA————16.59
EV/EBIT————23.07
Yield
Earnings Yield %————2.23
FCF Yield %————-17.79
Reference — adjusted share basis
Price (FY-end close, adj.)————19.71
EPS (adj.)8.33-0.434.540.260.44
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.